Friday, 20 Oct 2017

You are here

Managing Secondary Non-Response to Rituximab in Lupus

Rituximab, a chimeric anti-CD20 monoclonal antibody, has been effectively used in the treatment of multiple autoimmune disorders for over two decades.

But the response to rituximab has been shown to not be as effective in SLE as it is in RA. This discrepancy is believed to be attributed to production of pathogenic lupus antibodies produced by long-lived plasma cells and reduced effector activity resulting from interaction with FcgRIIb.

Although in majority of the cases retreatment with rituximab is effective there are cases of lupus patient who lost response to rituximab over time. In those cases patient presented with clinical non-response during retreatment, failure to deplete CD20+ B cells and severe infusion reactions after the second infusion of the repeat cycle.

This prospective 12-year study aimed to assess predictors of primary and secondary non-response to rituximab in SLE and to evaluate management of secondary non-depletion non-response (2NDNR) using alternative anti-CD20 agents.

125 lupus patient who met revised 1997 ACR classification criteria for SLE and were treated with rituximab were prospectively observed between 2004 and 2016.

Clinical response was measured as improvement of BILAG from grade A/B to grade C and no grade A/B flares. Peripheral blood B sell subsets were measured by HSFC (depletion defined as counts<0.0001X109/L) along with dsDNA antibodies by ELISA and anti-rituximab antibodies ( >140 AU/mL considered positive).

318 cycles of rituximab were administered in this study with overall good clinical response: 50% of patients experienced major clinical response, 32% partial clinical response and 18% were non-responders.

In the responder group, only younger age was associated with major clinical response to rituximab (OR 0.97, 95% CI 0.95 to 0.99; p=0.031).

Complete post-rituximab B cell depletion was associated with normal complement levels and lower pre-infusion plasmablasts. There was no difference in the serious infections rates between complete and incomplete depletion groups.

In patients who did not respond well to repeat cycles of rituximab (2NDNR group), 5/5 patient (100%) tested positive for anti-rituximab antibodies.

Risk factors for 2NDNR were lack of concomitant immunosuppressant (P=0.023) and higher pre-rituximab plasmablasts (p <0.001).

Five 2NDNR patients were switched to humanized anti-CD20 antibodies (3=ocrelizumab and 2=ofatumumab), which lead to completed CD20+ cell depletion in 4 out of 5 patients. One patient had substantially low counts (0.0016X109/L).

In summary, the study concluded that 1 out of 8 SLE patients will lose CD20+ depletion on repeat rituximab cycles regardless of prior response. Secondary non-response is associated with anti-rituximab antibodies and high pre-infusion plasmablasts levels, and can be prevented by concomitant use of oral immunosuppressants. In case of 2NDNR, alternative humanized anti-CD20 antibodies may be used effectively.  

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

BSR Guidelines on Lupus Management

In the UK, NICE has accredited the British Society of Rheumatology (BSR) to develop a guidance document on the management of systemic lupus erythematosus in adults.  The last published guidelines for lupus were published in 2008 by EULAR and in 2012 by the ACR.

IBD Associated with Increased risk of Autoimmune and Inflammatory Diseases

A registry based study has shown higher rates of immune mediated diseases (IMD) in patients with inflammatory bowel disease (IBD).

Researchers examined 47325 IBD patients from the Danish National Patient Registry and compared them to controls from a civilian registry and used ICD 10 codes to identify the diagnoses observed.

Primary Sjögren's Syndrome Guideline from the British Society for Rheumatology

The British Society of Rheumatology (BSR) has been accredited by NICE to develop a guidance document for the management of primary Sjögren's Syndrome intended for rheumatologists, general physicians, general practitioners, specialist nurses and other specialists (e.g. ophthalmologists, dental practitioners and ENT specialists),

Isolated SS-B Not Associated with Connective Tissue Disease

A one-year prospective study of 624 patients undergoing autoantibody testing for anti-SS-A and/or anti-SS-B autoantibodies finds that isolated anti-SS-B autoantibodies was not associated with features or the diagnosis of any specific connective tissue diseases (CTD).

Half of Takayasu's Arteritis Relapse

A French retrospective study of 318 Takayasu's arteritis (TA) patients shows that 50% of patients will relapse and experience a vascular complication ≤10 years from diagnosis.